Skip to content
Screener

Viridian Therapeutics, Inc. VRDN Q4 2025 Annual earnings

Reported February 26, 2026 · Before market open

Revenue$132.0KMiss by $18.2M
EPS-$1.08Miss by $0.18
Revenue estimate$18.4M
EPS estimate-$0.90

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$4.0M
EPS estimate-$0.99

Financials

Q4 2025

Income statement

See full
Revenue$132.0K+83.3%
Operating income-$122.7M-40.3%
Net income-$120.4M-51.0%

Balance sheet

See full
Cash & equivalents$212.4M+113%
Total debt$37.0M+1,357%
Total equity$722.2M+7.5%
Total assets$899.4M+21.1%

Cash flow

See full
Operating cash flow-$23.8M+67.6%
CapEx$240.0K+111%
Free cash flow-$24.0M+67.3%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$2.97B+95.6%
Enterprise value$2.79B+96.6%
P/S41.9×-4,986×

Profitability

See full
Operating margin-512.9%-256pp
Net margin-483.6%-241pp
FCF margin-390.8%-195pp

Returns & leverage

See full
Return on equity-49.2%+0.7pp
Debt / equity0.1×0.0×
Current ratio12.6×-2.8×

FAQ

When did Viridian Therapeutics, Inc. report Q4 2025 earnings?
Viridian Therapeutics, Inc. (VRDN) reported Q4 2025 earnings on February 26, 2026 before market open.
What were Viridian Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Viridian Therapeutics, Inc. reported revenue of $132.0K and eps of $-1.08 for Q4 2025.
Did Viridian Therapeutics, Inc. beat estimates in Q4 2025?
Revenue missed the consensus estimate of $18.4M by $18.2M. EPS missed the consensus estimate of $-0.90 by $0.18.
How did Viridian Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 83.3% from $72.0K a year earlier and eps declined 33.3% from $-0.81.
Where can I find Viridian Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-073391) and the 10-K periodic report (0001590750-26-000007) directly on SEC EDGAR. The filing index links above go to sec.gov.